Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Revenue (2020 - 2025)

Historic Revenue for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $18.2 million.

  • Pharming's Revenue fell 7569.37% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $362.3 million, marking a year-over-year increase of 614.1%. This contributed to the annual value of $297.2 million for FY2024, which is 2114.99% up from last year.
  • Pharming's Revenue amounted to $18.2 million in Q3 2025, which was down 7569.37% from $172.3 million recorded in Q2 2025.
  • Pharming's Revenue's 5-year high stood at $43.5 billion during Q1 2021, with a 5-year trough of -$43.3 billion in Q2 2021.
  • Moreover, its 5-year median value for Revenue was $66.7 million (2023), whereas its average is $70.4 million.
  • Its Revenue has fluctuated over the past 5 years, first crashed by 9999.8% in 2022, then skyrocketed by 950034.54% in 2024.
  • Quarter analysis of 5 years shows Pharming's Revenue stood at $93.2 million in 2021, then crashed by 41.42% to $54.6 million in 2022, then skyrocketed by 48.72% to $81.2 million in 2023, then rose by 14.13% to $92.7 million in 2024, then tumbled by 80.37% to $18.2 million in 2025.
  • Its Revenue stands at $18.2 million for Q3 2025, versus $172.3 million for Q2 2025 and $79.1 million for Q1 2025.